Immunocore to Present at Jefferies Healthcare Conference

Immunocore Holdings plc, a leading biotechnology firm, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The conference will feature a fireside chat scheduled for Thursday, June 6, 2024, at 2:30 p.m. Eastern Daylight Time (EDT). This event will be webcast live and can be accessed through Immunocore's official website under the 'Investors' section.

Immunocore, listed on Nasdaq under the symbol IMCR, is at the forefront of developing innovative immunotherapeutic solutions aimed at improving patient outcomes in cancer, infectious diseases, and autoimmune disorders. The company is renowned for its TCR bispecific immunotherapies, branded as ImmTAX, which stands for Immune mobilizing monoclonal TCRs Against X disease. This proprietary platform is designed to combat a wide array of diseases, leveraging off-the-shelf products to create a versatile and comprehensive treatment pipeline.

The company currently has five clinical-stage programs focused on oncology and infectious diseases, alongside advanced pre-clinical programs targeting autoimmune diseases. Among its most noteworthy achievements is the approval of KIMMTRAK, a TCR therapeutic addressing HLA-A*02:01-positive adult patients suffering from unresectable or metastatic uveal melanoma. This approval spans several regions, including the United States, European Union, Canada, Australia, and the United Kingdom.

During the Jefferies Global Healthcare Conference, company representatives are expected to delve into various aspects of Immunocore's progress and future plans. Topics on the agenda include the commercialization and therapeutic promise of KIMMTRAK, expected clinical benefits, and plans for expanding its availability into new markets. Moreover, Immunocore will discuss its ongoing and future clinical trials, including a randomized Phase 2/3 clinical trial for advanced melanoma and investigations into PRAME and MAGE-A4.

The presentation will also cover the company's broader strategic initiatives, including its efforts to expand access to its innovative therapies and ongoing collaborations with third parties. These collaborations are crucial for the successful commercialization of KIMMTRAK and other pipeline products.

However, the company cautions that their forward-looking statements are subject to numerous risks and uncertainties, which could significantly affect actual outcomes. These statements include, but are not limited to, assumptions about the clinical benefits, market potential, and regulatory approvals of their products. Additionally, external factors such as the ongoing COVID-19 pandemic, geopolitical tensions, and supply chain disruptions may impact the company’s operations and strategic milestones.

Immunocore also highlights the importance of maintaining regulatory approval and intellectual property protection for its growing list of therapeutic candidates. The company's future success is dependent on its ability to navigate these challenges while continuing to innovate and bring new treatments to market.

Investors and stakeholders interested in Immunocore's advancements and future plans are encouraged to tune into the live webcast of the fireside chat. For those unable to attend the live session, a replay will be made available on the company’s website for a limited period.

In conclusion, Immunocore remains committed to advancing its pioneering immunotherapies to address critical unmet medical needs across various disease areas. The upcoming presentation at the Jefferies Global Healthcare Conference will provide valuable insights into the company’s ongoing efforts and future directions.